These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 25151981

  • 1. A survey on "Trojan Horse" peptides: opportunities, issues and controlled entry to "Troy".
    Shi NQ, Qi XR, Xiang B, Zhang Y.
    J Control Release; 2014 Nov 28; 194():53-70. PubMed ID: 25151981
    [Abstract] [Full Text] [Related]

  • 2. Cell penetration: scope and limitations by the application of cell-penetrating peptides.
    Reissmann S.
    J Pept Sci; 2014 Oct 28; 20(10):760-84. PubMed ID: 25112216
    [Abstract] [Full Text] [Related]

  • 3. Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses.
    Zappavigna S, Misso G, Falanga A, Perillo E, Novellino E, Galdiero M, Grieco P, Caraglia M, Galdiero S.
    Curr Pharm Biotechnol; 2016 Oct 28; 17(8):700-22. PubMed ID: 27087493
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
    Shi NQ, Li Y, Zhang Y, Shen N, Qi L, Wang SR, Qi XR.
    ACS Appl Mater Interfaces; 2017 Dec 06; 9(48):41767-41781. PubMed ID: 29161013
    [Abstract] [Full Text] [Related]

  • 8. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules.
    Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F.
    Peptides; 2014 Jul 06; 57():78-94. PubMed ID: 24795041
    [Abstract] [Full Text] [Related]

  • 9. Cell-penetrating peptides with nanoparticles hybrid delivery vectors and their uptake pathways.
    Dowaidar M.
    Mitochondrion; 2024 Sep 06; 78():101906. PubMed ID: 38797356
    [Abstract] [Full Text] [Related]

  • 10. Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges.
    Huang YW, Lee HJ, Tolliver LM, Aronstam RS.
    Biomed Res Int; 2015 Sep 06; 2015():834079. PubMed ID: 25883975
    [Abstract] [Full Text] [Related]

  • 11. Cell-penetrating peptides as tools to enhance non-injectable delivery of biopharmaceuticals.
    Kristensen M, Nielsen HM.
    Tissue Barriers; 2016 Sep 06; 4(2):e1178369. PubMed ID: 27358757
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides.
    Lindberg S, Copolovici DM, Langel U.
    Ther Deliv; 2011 Jan 06; 2(1):71-82. PubMed ID: 22833926
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Advances in cell penetrating peptides and their functionalization of polymeric nanoplatforms for drug delivery.
    Tian Y, Zhou S.
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Mar 06; 13(2):e1668. PubMed ID: 32929866
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides.
    Bolhassani A, Jafarzade BS, Mardani G.
    Peptides; 2017 Jan 06; 87():50-63. PubMed ID: 27887988
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems.
    Kamei N, Bech Nielsen EJ, Nakakubo T, Aoyama Y, Rahbek UL, Pedersen BL, Takeda-Morishita M.
    J Pharm Sci; 2016 Feb 06; 105(2):747-753. PubMed ID: 26869427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.